e Objectives: Many children with HIV infection now survive into adulthood. This study explored the impact of vertically acquired HIV in the era of antiretroviral therapy on the development of humoral immunity.
Introduction
Vertical transmission of HIV infection remains a global problem. With increasing use of antiretroviral therapy (ART), children are surviving into adulthood. Debate remains regarding timing of initiation of ART in childhood. Until recently, guidelines [1] recommended that all infants receive ART from diagnosis; however, treatment in older children and adolescents was conditional on disease parameters, acknowledging poor-quality evidence to inform practice. Following a recent study in adults [2] , latest WHO guidance is to treat all patients, including children.
The availability of a cohort of vertically infected young adults provides the first opportunity to understand the
Patients, materials and methods
HIV-infected patients aged 12-25 years were recruited from London HIV clinics (2010) (2011) (2012) . Patients with history of Pnc immunization were excluded. Patients were subdivided into those infected as adolescents/young adults by parenteral/sexual (horizontal) route more than 2 years previously (HIV-H; n ¼ 29) and those infected by MTCT (vertically) (HIV-V; n ¼ 64). Healthy adult volunteers aged 18-25 years formed the control group (CON; n ¼ 51) (National Research Ethics Service ethics: 10/H0713/1).
Anonymized participant identifiers for those in paediatric care were matched to the Collaborative HIV Paediatric Study, a cohort of all children with diagnosed HIV in the UK and Ireland [29] , to obtain data on CD4 þ cell counts, viral loads and ARTexposure. Data for the HIV-H group were obtained from clinical records.
Blood was taken pre (D0), 1 month (D28) and 1 year (1 y) postimmunization with PPV (Pneumovax 23 TM ). D0 blood was used for flow cytometry and serum studies and postimmunization blood for serum studies only. CD4 þ cell count was determined by flow cytometric assay and HIV viral load using a bDNA assay (Bayer Diagnostics; lower limit of detection 50 copies/ml).
Serum Pnc immunoglobulin (Ig)M and IgG antibody concentration to eight and 10 serotypes, respectively were analysed using a flow-based multiplex assay (modified from Lal et al. [30] ).
Serotype coverage was measured at concentrations of 0.35 and 1.3 mg/ml, values used clinically to diagnose selective antibody deficiency in the UK and USA, respectively [31] [32] [33] [34] .
Functional antibodies to four serotypes were measured in a multiplexed opsonophagocytic killing (OPK) assay, as previously described [35] . Values are expressed as an OPK assay titre equivalent to the reciprocal of the serum dilution required to produce 50% killing of the relevant serotype.
Absolute numbers and relative percentages of cells in the B-cell lineage were measured in whole blood (in EDTAcoated plastic tubes) by flow cytometry. The following antibodies were used: CD19-PeCy, IgM-APC, IgDAlexa Fluor 700, Ki-67-FITC (BD Biosciences, Oxford, Oxfordshire, UK), CXCR5-PerCP-Cy5.5 (Insight Biotechnology, UK), CD95-Pacific Blue, CD38-Qdot 605, CD27-Qdot 655, CD10-Qdot 800, CD21-Qdot 705; self-conjugated, Bcl-2-PE (Invitrogen Ltd., Paisley, Renfrewshire, UK). Blood was washed twice, incubated with viability dye, rewashed and incubated with extracellular antibodies for 15 min in the dark at room temperature. Following red cell lysis using whole blood lysis buffer (BD Biosciences), cells were washed twice and fixed in CellFix (BD Biosciences) before analysis. For intracellular staining, cells were permeabilized using 0.5% bovine serum albumin (Sigma-Aldrich, Oxford, Oxfordshire, UK) in PBS and 0.1% Saponin (Sigma-Aldrich), incubated with intracellular antibodies for 30 min at 4 8C in the dark, washed and refixed.
Assays were performed using an LSRII flow cytometer and data analysed with FacsDiva (BD Biosciences) software. Flowjo software [version 7.6.4 (Treestar Inc., Ashland, Oregon. USA)] was used for auto-compensation using compensation beads (BD Biosciences) and analysis.
Statistical analyses were performed using SPSS software, version 21 (IBM, Armonk, New York, USA), and GraphPad Prism software (GraphPad Software Inc., San Diego, California, USA), version 6. As data were not normally distributed, nonparametric statistical tests were used. Analysis of variance and Mann-Whitney U tests were used for comparisons of continuous variables between groups.
Results
Demographic and clinical characteristics of all patient groups are shown (Table 1) . Analysis of cellular and serological data by sex showed no significant difference (data not shown). Age of viral control (defined as age at first negative viral load assay after commencing ART) is shown for HIV-V (Fig. S1 , http://links.lww.com/ QAD/A922). By transition to adult services, 29% of the HIV-V cohort had achieved and maintained a viral load below the limit of detection. 20% of the cohort had never achieved viral control, including three children off ART.
Pnc serology data are presented by percentage serotype coverage at 0.35 or more and 1.3 mg/ml (Fig. 1a and b ) (full data set Supplementary Fig. S2 , http://links.lww. com/QAD/A922). Baseline serology to Pnc polysaccharide (PncPS) varied considerably within all cohorts both within and between serotype. Spread of data and serotype dominance were similar in all cohorts; however, IgM and IgG serotype coverage were significantly reduced in HIV-V. IgG serotype coverage at 1.3 mg/ml was also reduced in HIV-H (Fig. 1b) . Postimmunization PncPS IgG and IgM increased in all cohorts at both D28 and 1 y. However, IgM and IgG serotype coverage remained considerably reduced in both HIV-infected cohorts at D28 and 1 y compared with controls. There was no significant difference in preimmunization IgM or IgG concentrations between these cohorts, but patients with viral load below the limit of detection at D0 had greater 1-y IgM and IgG serotype coverage than viraemic patients, though still lower than in CON. Coverage was greatest in those patients with early viral control (Fig. 1c) counts more than 200 Â 10 9 cells/l so were not included in this analysis.
To evaluate whether natural immunity or acute response to immunization predicts lasting immunity, we correlated preimmunization and D28 postimmunization IgG and IgM concentration with 1-y IgG concentration. We found a strong correlation between all time points (data not shown); however, 1-y IgG serotype coverage correlated most consistently with D0 rather than D28 postimmunization antibody responses in all cohorts (Supplementary Table 1 , http://links.lww.com/QAD/ A922; graphs in Supplementary Fig. S3 , http:// links.lww.com/QAD/A922), suggesting that natural immunity rather than acute response to immunization best predicts lasting immunity.
In-vitro OPK activity was assessed in HIV-Vand CON at both D0 and 1 y. OPK activity was significantly reduced for all serotypes in HIV-V ( Fig. 1e ) with up to 50% of individuals showing no killing activity compared with less than 10% of the control group (Fig. 1f ). In patients with early control of viral load (VL) (HIV-V e ), OPK was closer to control values and greater than that of patients with late viral control (HIV-V l ) for most serotypes (Fig. 1g ). In addition, in HIV-V patients with CD4
þ cell counts less than 200 Â 10 9 cells/l, there was no OPK activity to the majority of serotypes (Fig. 1h) .
To explore quality of PncPS immunoglobulin, OPK activity was correlated with serum PncPS immunoglobulin concentration. OPK correlated with PncPS IgG and IgM concentration in both cohorts with IgM concentrations showing the strongest correlation (Fig. 2) .
Assessment of concentration as a predictor of function in HIV-V showed that PncPS immunoglobulin 0.35 mg/ml or less, whilst sensitivity at identifying most individuals with no OPK had poor specificity, with several patients with antibody concentration at least 0.35 mg/ml having no or low OPK activity.
Flow cytometric analysis of B-cell lineage and dynamic markers was assessed in all cohorts to determine whether perturbations reported in young children and HIV-H adults are also seen in vertically infected young adults. Total B-cell numbers were reduced in the HIV-H cohort (P ¼ 0.007) compared with both CON and HIV-V cohorts, and there was trend for absolute B-cell count to be greater with viral control in the HIV-V cohort (Fig. 3a) .
Marked differences in circulating B-cell populations were seen between cohorts ( Fig. 3b ; Gating strategy in Supplementary Fig. S4 , http://links.lww.com/QAD/ A922). In HIV-V, naive cells dominated with reduction in MZM and SwMem B-cells and mature preplasmablast populations (Fig. 3c(i-iv) ) compared with controls. CD10 þ recent bone marrow emigrants (BMEs) and transitional populations increased (Fig. 3c(v and vi) ) and a large proportion of the B-cell population was CD21low (Fig. 3c(vii) ). These cells comprised mature activated (Fig. 3c(viii) ) and exhausted/anergic (Fig. 3c(ix) ) phenotypes, normally circulating at very low levels in healthy controls. The cohort with controlled viraemia for 10 years (HIV-V e ), when analysed separately, showed no difference with control data for absolute B-cell count, transitional cell, plasmablast, CD21low, MZM, mature activated and exhausted/anergic cell phenotype (P > 0.05). When compared with HIV-V, immature BME and mature activated cells were increased in HIV-H, and HIV-V showed reduction in MZM and SwMem populations. When compared with CON, HIV-H showed increased transitional B-cells and BME, and increased plasmablasts, mature activated and exhausted/ anergic populations (Fig. 3c) . These changes were not significantly affected by viral control.
Surrogate markers of cell turnover, trafficking and susceptibility to apoptosis were assessed using Ki67, CXCR5 and CD95/Bcl2 expression, respectively (Gating Strategy in Supplementary Fig. S5a , http:// links.lww.com/QAD/A922; phenotype-specific expression in Supplementary Fig. S5b , http://links.lww.com/ QAD/A922). In the control population, there was lowlevel replication, determined by Ki67 positivity, in most B-cell subpopulations, with the exception of plasmablasts and mature activated B-cells. CXCR5 expression was greatest in the naive population, including recent BMEs and was seen at low level in the CD21low population. CD95 expression was highest in activated and transitional B-cells and lowest in the mature naive B-cell population. In contrast, Bcl2 expression was higher in memory populations and reduced in naive and transitional populations. Lineage-specific expression profiles were similar between cohorts and are presented for the total B-cell population for intercohort comparisons. HIV infection was associated with increased Ki67 (Fig. 3d(i) ) and CD95 expression (Fig. 3d(ii) ) and reduced CXCR5 (Fig. 3d(iii) ) in both HIV-H þ and HIV-V þ cohorts. Bcl2 expression was reduced in the HIV-V þ cohort (P ¼ 0.001) and not impaired in the HIV-H þ (Fig. 3d(iv) ). The HIV-V cohort with controlled viraemia for 10 years (HIV-V e ) showed no difference from control data for CD95, CXCR5 and Bcl2 (P > 0.05).
B-cell profiles were correlated with Pnc serology data in HIV-V to determine whether changes in B-cell lineage and dynamic phenotype may predict poor Pnc immunity and vaccine responsiveness. Significant correlations were identified between prevaccination cell phenotypic data and serotype coverage and/or OPK activity at 1-year postimmunization in HIV-V for some B-cell subpopulations (Table 2 ; graphs available in Supplementary Fig. S6 , http://links.lww.com/QAD/ A922). MZM B-cell numbers correlated with D0 IgM and postimmunization IgG serotype coverage; correlation with OPK activity was also seen for two serotypes. There was no relationship between SwMem cell numbers and Pnc serology. The increase in the CD21low B-cell population correlated negatively with IgG serotype coverage and OPK and anergic cell numbers correlated negatively with both IgM and IgG serotype coverage and OPK activity postimmunization. Of the dynamic markers, the strongest correlations were seen in CXCR5 expression, which correlated positively with IgM and IgG serotype coverage postimmunization and serum OPK activity. Bcl2 expression also correlated with postimmunization IgG and IgM serotype coverage. Viral load at time of immunization correlated most strongly with these serological parameters and more consistently with OPK activity and a weaker relationship was generally seen with CD4 þ cell count (Table 2 ). No consistent relationship was seen between numbers of other B-cell phenotypes, CD95 and Ki67 expression and PncPS IgG concentrations or OPK activity.
The HIV-H cohort was smaller with paired serology and phenotype analysis available for 23 and 16 patients preimmunization and postimmunization, respectively, limiting the power of the analysis. There was no correlation between MZM numbers and serotype coverage preimmunization or postimmunization, and although a positive correlation was seen with CXCR5 expression, this did not reach significance (data not shown). 
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Discussion
By characterizing Pnc immunity, determined by PncPS IgM and IgG serotype coverage and OPK activity preimmunization and postimmunization with PPV, we have shown impaired natural and vaccine-induced immunity to pneumococcus in vertically-infected HIV patients growing up in the UK. Twenty percent of our cohort had never achieved viral control by the time of transition to adult services. Furthermore, of those who did achieve viral control at some stage, in only 30% was this sustained. Subset analysis by viral control showed that whilst natural immunity is not improved with early viral control, vaccine-induced immunity is considerably better (although still less than in healthy controls). Detectable viraemia at time of immunization is associated with the most impaired vaccine responses and in the few patients with CD4 þ cell count less than 200 Â 10 9 cells/l there was little evidence of a serum response to immunization.
The study is the first to our knowledge to show that both natural IgM and IgG Pnc serotype coverage are reduced in patients with vertically-acquired HIV and not fully restored with viral control. The marked reduction in natural immunity seen in this cohort is likely due to MZM [8, 10] younger children have not shown reduced natural immunity. Bamford et al. and others have reported preimmunization Pnc IgG concentrations to be similar in HIV-V and CON groups [36] [37] [38] [39] [40] . This discrepancy may reflect different ages of the study cohorts as natural Pnc immunity develops through childhood [41] (thus a deficit may only be evident in older cohorts) or may reflect disease duration. Female sex has been reported to be associated with an improved prognosis in HIV infection [42] ; however, we found no evidence of a difference by sex in either the serological or cellular analysis, suggesting that there is not a sex-dependent effect on the B-cell compartment in adolescents with vertically acquired infection.
In our study, viral control before 10 years was not associated with preservation of natural immunity, suggesting that damage to Pnc immunity occurs early in disease. It may be that with perinatal viral control, as is now recommended [43] , development of natural immunity may be preserved. Natural immunity in HIV-H was also impaired, with IgM and IgG serotype coverage reduced at the higher concentration of 1.3 mg/ml. Viral control was associated with increased IgG concentrations, however these remained less than in controls, supporting the idea that control of viral load in adults is also important to protect natural immunity to pneumococcus [27, 44] .
In contrast to the significant, sustained increase postimmunization in both IgM and IgG serotype coverage in controls, both HIV-infected cohorts showed impaired IgM and IgG responses to PPV. Viral control at immunization was associated with greater vaccine responsiveness, and early control of viral load was associated with highest postimmunization PncPS antibody concentrations, although in all HIV-V subgroups, concentrations remained less than controls. This may suggest impairment of both MZM and SwMem responses, and is consistent with previous data in both children and adults showing impaired serum response to PPV in HIV [10, [45] [46] [47] . [20] , hyporeactivity to proliferation stimuli [48] and abnormal B-cell trafficking [23] . Viral control was associated with normalization of B-cell profiles but vaccine responses remained poor. There are a number of possible explanations for this, including loss of diversity of the genetic antibody repertoire [49] [50] [51] [52] . However, we favour the concept of original antigenic sin
Childhood HIV and pneumococcal immunity Eisen et al. 1873 [54, 55] . However, the data we have generated for the HIV-H cohort suggest that natural IgG immunity to pneumococcus is impaired in those acquiring infection in adulthood, suggesting that viral control should be maintained through life to protect humoral immune competence.
Whilst PncPS IgG concentration is used as a surrogate for protective immunity to IPD, putative protective concentration of IgG is unclear and additional correlates of protection, including OPK activity to inform immunization strategy have been developed to address qualitative differences in PncPS antibody function [56] . We found that the correlations between PncPS IgM and IgG concentrations and OPK activity were similar in both CON and HIV-V cohorts. However, whilst IgG is considered the dominant isotype for Pnc protection, we showed that PncPS IgM concentration correlated most strongly with OPK. In addition, several patients with PncPS IgG more than 0.35 mg/ml had low/no OPK activity emphasizing difficulty in establishing predicted protective values for PncPS IgG concentration in HIV infection. Early viral load control was associated with improved OPK for serotypes 6B and 14; however, OPK remained impaired for type 4 and 23F. The reason for this is unclear. ART is known to reverse, at least partially, several of the immunological effects of HIV believed to underlie poor PPV efficacy, including VH3 repertoire disruption [57] [58] [59] [60] , apoptosis [9, 14, 16, 17, 20, 61] and proliferation [24, 25] , but this would be expected to achieve improvement for all serotypes. Normalization of some B-cell populations with ART may be responsible; it is possible that relative contribution of different B-cell populations to serotype-specific OPK varies by serotype. It is interesting that in our study, 6B and 14 OPK activity correlated positively with MZM numbers, which remain impaired despite ART, whilst 4 and 23F OPK did not.
Horizontally infected patients appeared less affected by reduction in MZM and SwMem than their vertically infected counterparts. This may result from longer duration of infection and/or the impact of HIV at a vulnerable stage of immune development in HIV-V. Regardless, it indicates that vertically infected children are at particular risk from infection in adulthood.
Our data indicate that vertically infected children are at considerable risk of humoral immune defects with potential for profound impact on adult health. Early and sustained control of HIV replication by ART appears to mitigate against these humoral defects. This is consistent with other data, in younger children, showing benefit of early-life ART [28] , and might perhaps have been more pronounced in our study had it been possible to examine impact of viral control within the first year of life. 
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